프로메디우스㈜
Seoul, KR · Founded 2019 · 22 employees on LinkedIn · 1 known investors
Promedius develops AI software that supports osteoporosis diagnosis from chest X-rays and performs muscle and fat segmentation from abdominal CT scans. The company builds medical imaging AI tools aimed at supporting aging-related health diagnostics.
Also known as PROMEDIUS · Promedius Inc · PROMEDIUS INC. · 프로메디우스
Investors · 1
Company profile
researched Aug 2026PROMEDIUS INC. (프로메디우스㈜) is a Seoul-based medical artificial intelligence company that develops imaging analysis software oriented around aging-related health. Its stated mission is to enable "healthy aging through AI."
The company's product line comprises two AI software offerings: a chest X-ray based osteoporosis diagnosis support tool, and an abdominal CT based muscle and fat segmentation tool. The company also makes an interactive demonstration of its AI technology available through its website.
Latest developments
In November 2025 Promedius announced an AI integration agreement with Siemens Healthineers China. Research on deep-learning-based opportunistic osteoporosis screening on chest radiographs, incorporating uncertainty and calibration, is associated with the WCO-IOF-ESCEO congress in January 2026. The company held its 40th internal town hall meeting in November 2025.
▸Full profile — technology, go-to-market, geography
Technology
Promedius applies deep learning to routine radiological images. Its osteoporosis application performs opportunistic screening from chest radiographs, with research work addressing uncertainty estimation and model calibration in that setting. A second application segments muscle and fat tissue from abdominal CT scans.
Go-to-market
Alongside direct promotion of its products and an online technology demo, the company pursues integration partnerships with medical imaging vendors, as evidenced by its agreement with Siemens Healthineers China.
Geography
The company is headquartered at 13, Olympic-ro 35da-gil, Songpa-gu, Seoul 05510, Republic of Korea. It has an announced AI integration agreement with Siemens Healthineers China, indicating activity oriented toward the Chinese market.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 3
launches, deals, and filingsWork titled "Deep learning based opportunistic osteoporosis screening on chest radiographs with uncertainty and calibration" listed in connection with the WCO-IOF-ESCEO congress.
Promedius announced an agreement to integrate its AI with Siemens Healthineers China.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- 프로메디우스㈜promedius.ai · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 프로메디우스㈜ do?
- Korean medical-imaging AI company building osteoporosis screening and body-composition analysis software for healthy aging.
- Who are 프로메디우스㈜'s investors?
- 프로메디우스㈜'s investors include Crit Ventures.
- Where is 프로메디우스㈜ headquartered?
- 프로메디우스㈜ is headquartered in Seoul, KR.